Free MDSteps Library Preview
You’ve viewed 0 of 5 free topics.
Unlock Unlimited Articles - Free for 3 Days
MDSteps- USMLE® Reference Library

Immune TTP — ADAMTS13, Plasma Exchange, Steroids, and Caplacizumab

System: Hematology Oncology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Suspect iTTP with MAHA and thrombocytopenia; send ADAMTS13 urgently and begin plasma exchange plus high-dose steroids immediately; add caplacizumab when iTTP is likely to reduce time to platelet recovery and relapses.

Key Points

  • Stabilize ABCs; treat life‑threatening derangements immediately.
  • Confirm diagnosis early with highest‑yield imaging/labs.
  • Initiate guideline‑based therapy and escalate by response.
  • Plan disposition and follow‑up explicitly.

Clinical Synopsis & Reasoning

Immune TTP is a microangiopathy from severe ADAMTS13 deficiency. Treat presumptively when suspected: daily plasma exchange plus high‑dose corticosteroids. Add caplacizumab early to shorten time to platelet recovery and reduce exacerbations; introduce rituximab to target the autoantibody. Monitor for relapse and complications.


Treatment Strategy & Disposition

Immune TTP is a microangiopathy from severe ADAMTS13 deficiency. Treat presumptively when suspected: daily plasma exchange plus high‑dose corticosteroids. Add caplacizumab early to shorten time to platelet recovery and reduce exacerbations; introduce rituximab to target the autoantibody. Monitor for relapse and complications.


Epidemiology / Risk Factors

  • Risk varies by comorbidity and precipitating factors

Initial Targets

ParameterTarget/Action
HemodynamicsMaintain perfusion; avoid hypotension
MonitoringSerial exam, labs, and imaging
TherapyStart early, reassess, de‑escalate when appropriate

Investigations

TestRole / RationaleTypical FindingsNotes
CBCScreen leukocytosis/anemiaContext‑specificTrend response
BMPElectrolytes/renal functionDerangements commonReplace K+/Mg2+
Key imagingCondition‑specific (CTA/MRI/Endoscopy)See textDo not delay when red flags

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
Therapeutic plasma exchangeImmunotherapyImmediateFirst‑line with steroidsAccess/bleeding risks
Caplacizumabanti‑vWF nanobodyHoursAdd when iTTP likelyBleeding risk; with PEX/steroids
MethylprednisoloneGlucocorticoidHoursImmunosuppressionHyperglycemia, infection

Prognosis / Complications

  • Outcome depends on timeliness of diagnosis and definitive therapy

Patient Education / Counseling

  • Explain red flags, adherence, and follow‑up plan

References

  1. ASH Review: Management of iTTP — Link
  2. ISTH TTP Guidelines Update (2025) — Link

Meet MDSteps: Smarter USMLE® Prep

MDSteps streamlines your study with an adaptive QBank (19,000+ high-yield MCQs across all 3 Steps), full CCS case simulations for Step 3 with live vitals and timed orders, and an exam-readiness dashboard that turns practice into insight. Build mastery by system and discipline, auto-create missed-item decks (Anki-exportable), and keep momentum with pacing guidance, trend lines, and suggested next sessions—so every block moves you closer to test-day confidence.

Compared with staples like UWorld and AMBOSS, MDSteps aims to give you the best of both worlds: exam-style practice that adapts to you, plus real-time analytics and a full CCS runner—all in one place. If you want targeted, exam-relevant reps with feedback that actually changes how you study, MDSteps is built for you.

Eplore MDSteps

You’ve reached your free library limit

You’ve viewed 5 of 5 free MDSteps Library topics.

Unlock full access to the MDSteps USMLE® Library, adaptive QBank, CCS simulator, and readiness analytics with a free trial.

  • Full access to all reference topics
  • 9,000+ NBME-style questions with teaching-grade rationales
  • Realistic CCS cases with live vitals
  • Exam readiness dashboard & study insights